Reye’s Syndrome Market Research Report - Global Forecast till 2023

Global Reye's Syndrome Market Research Report: By Diagnosis (Tests, Imaging, Biopsy), By Treatment (Electrolytes And Fluids, Corticosteroids, Ammonia Detoxicants, Insulin), By End User (Hospitals & Clinics And Diagnostic Centers) – Forecast till 2023

ID: MRFR/MED/3860-HCR | | Region: Global | 90 pages

Market Scenario:
Reye’s syndrome is a rare but serious illness that causes swelling in the liver and brain. The disease is most prevalent in the adolescent population who are recovering from a viral infection such as chickenpox and the flu. Few symptoms of the disease are inclusive of diarrhea, rapid breathing, seizures, and others. Application of aspirin in the treatment procedures of the viral infections is linked with the disease. Increasing prevalence of influenza and teenage population are the major drivers of the market growth. According to the 2015-2016 Influenza Burden Estimates of the Centers for Disease Control and Prevention, 9.2-35.6 million cases of influenza led to 140,000-710,000 hospitalizations and caused 12,000- 56,000 deaths annually since 2010. Moreover, according to the Child Trends, the number of children under 18 years of age is projected to increase from 74.1 million to 78.2 million by 2040. Additionally, increasing per capita healthcare expenditure and developing biotechnology & pharmaceutical sector within the developing economies across the world are estimated to fuel the market growth during the forecasted period. However, lack of awareness and limited treatment options may restrain the market growth during the forecast period.
The global market for Reye's syndrome is estimated to grow at an approximate CAGR of 7.20% from 2017 to 2023.
Intended Audience

Pharmaceutical Companies
Biotechnological Institutes
Government and Private Laboratories
Research and Development (r&d) Companies
Medical Research Laboratories
Market Research and Consulting Service Providers

Figure 1:- Global Reye’s Syndrome Market share, by Region

Sources: WHO, annual reports, press release, white paper, and company presentation

Key players in global Reye’s syndrome market
General Electric Company (U.S.), Siemens Healthcare GmbH (Germany), CANON MEDICAL SYSTEMS CORPORATION (Japan), Koninklijke Philips N.V. (The Netherlands), NeuroLogica Corp. (U.S.), Sumitomo Corporation (Japan), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), AstraZeneca (U.K), Eli Lilly and Company (U.S.), Biocon (India), Ypsomed (Switzerland), BD (U.S.), ARGON MEDICAL (U.S.), and others.
Segmentation
The global Reye’s syndrome market is segmented on the basis of diagnosis, treatment and end users.
On the basis of the diagnosis, the market is segmented into tests, biopsy, imaging, and others. The test segment is sub-segmented into blood tests, urine tests, and others. The biopsy segment is sub-segmented into liver biopsy, skin biopsy, and others. The imaging segment is sub-segmented into computerized tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and others.
On the basis of the treatment, the market is categorized into electrolytes and fluids, corticosteroids, ammonia detoxicants, insulin, and others.
On the basis of end users, the market is segmented into hospitals & clinics, research laboratories, diagnostic centers, and others.
Research Methodology

Sources: WHO, annual reports, press release, white paper, and company presentation
Regional Analysis:
The Americas dominate the global Reye’s syndrome market due to the presence of a well-developed healthcare sector and rising healthcare expenditures. Moreover, the adolescent population which is susceptible to influenza is increasing, creating favorable backgrounds for the market growth. Additionally, the presence of the developed economies and market key players within the region are estimated to fuel the market growth during the forecast period.
Europe is the second largest market for Reye’s syndrome, which is followed by Asia Pacific. Availability of funds for research, huge patient population and government support for research & development are the major drives for the growth of the market within the region.
Asia Pacific is the fastest growing region for the market due to the presence of continuously developing economies like India and China which have developing biotechnology and pharmaceutical industries. Additionally, the presence of huge opportunities within the region fuels the growth. According to the Indian Brand Equity Foundation in 2016, India’s pharmaceuticals market is expected to reach USD 45 billion by 2020 from USD 18 billion in 2012.
On the other hand, the Middle East & Africa has the least share in the global Reye’s syndrome market due to the presence of poor economies, especially within the African region. A majority of the market of this region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure.



Frequently Asked Questions (FAQ) :


Global Rege’s Syndrome market is expected to expand at 7.20% CAGR from 2017 to 2023.

High prevalence of influenza among teens is the primary driver of the global Rege’s syndrome market.

Lack of awareness of the disease and limited treatment options are factors expected to impede the global Rege’s Syndrome market growth.

The Americas will dominate in the global Rege’s Syndrome market till 2023.

Merck & Co., Inc., Siemens Healthcare GmbH, Ypsomed, Eli Lilly and Company, BD, AstraZeneca, Biocon, Sumitomo Corporation, General Electric Company, Novartis AG, Koninklijke Philips N.V., Pfizer Inc., ARGON MEDICAL, NeuroLogica Corp., and CANON MEDICAL SYSTEMS CORPORATION are prominent players of the global Rege’s Syndrome market.

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Reye’s Syndrome Market, by Diagnosis

6.1 Introduction

6.2 Tests

Market Estimates & Forecast, 2017 – 2023

6.2.1 Blood Tests

6.2.2 Urine Tests

6.2.3 Others

6.3 Biopsy

Market Estimates & Forecast, 2017 – 2023

6.3.1 Liver Biopsy

6.3.2 Skin Biopsy

6.3.3 Others

6.4 Imaging

Market Estimates & Forecast, 2017 – 2023

6.4.1 Computerized Tomography (CT)

6.4.2 Magnetic Resonance Imaging (MRI)

6.4.3 Positron Emission Tomography (PET)

6.4.4 Others

6.5 Others

Chapter 7. Global Reye’s Syndrome Market, by Treatment

7.1 Introduction

7.2 Electrolytes and Fluids

Market Estimates & Forecast, 2017 – 2023

7.3 Corticosteroids

Market Estimates & Forecast, 2017 – 2023

7.4 Ammonia Detoxicants

Market Estimates & Forecast, 2017 – 2023

7.5 Insulin

Market Estimates & Forecast, 2017 – 2023

7.6 Others

Chapter 8 Global Reye’s Syndrome Market, by End User

8.1 Introduction

8.2 Hospitals & Clinics

Market Estimates & Forecast, 2017 – 2023

8.3 Research Laboratories

Market Estimates & Forecast, 2017 – 2023

8.4 Diagnostic Centers

Market Estimates & Forecast, 2017 – 2023

8.5 Others

Chapter 9. Global Reye’s Syndrome Market, by Region

9.1 Introduction

9.2 America

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

Chapter 10. Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11. Company Profiles

11.1 ARGON MEDICAL

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials Overview

11.1.4 Key Developments

11.1.5 SWOT Analysis

11.2 AstraZeneca

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 BD

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Biocon

11.4.1 Company Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 CANON MEDICAL SYSTEMS CORPORATION

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 Eli Lilly and Company

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 General Electric Company

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Koninklijke Philips N.V.

11.8.1 Overview

11.8.2 Product Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Reye's syndrome industry

Chapter 13 Appendix


LIST OF TABLES

Table 1 Reye’s Syndrome Industry Synopsis, 2017 – 2023

Table 2 Global Reye’s Syndrome Market Estimates and Forecast, 2017 – 2023, (USD Million)

Table 3 Global Reye’s Syndrome Market by Region, 2017 – 2023, (USD Million)

Table 4 Global Reye’s Syndrome Market by Diagnosis, 2017 – 2023, (USD Million)

Table 5 Global Reye’s Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 6 Global Reye’s Syndrome Market by End Users, 2017 – 2023, (USD Million)

Table 7 North America Reye’s Syndrome Market by Diagnosis, 2017 – 2023, (USD Million)

Table 8 North America Reye’s Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 9 North America Reye’s Syndrome Market by End Users, 2017 – 2023, (USD Million)

Table 10 U.S. Reye’s Syndrome Market by Diagnosiss, 2017 – 2023, (USD Million)

Table 11 U.S. Reye’s Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 12 U.S. Reye’s Syndrome Market by End Users, 2017 – 2023, (USD Million)

Table 13 Canada Reye’s Syndrome Market by Diagnosiss, 2017 – 2023, (USD Million)

Table 14 Canada Reye’s Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 15 Canada Reye’s Syndrome Market by End Users, 2017 – 2023, (USD Million)

Table 16 South America Reye’s Syndrome Market by Diagnosis, 2017 – 2023, (USD Million)

Table 17 South America Reye’s Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 18 South America Reye’s Syndrome Market by End Users, 2017 – 2023, (USD Million)

Table 19 Europe Market Reye’s Syndrome by Diagnosis, 2017 – 2023, (USD Million)

Table 20 Europe Reye’s Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 21 Europe Reye’s Syndrome Market by End Users, 2017 – 2023, (USD Million)

Table 22 Western Europe Reye’s Syndrome Market by Diagnosis, 2017 – 2023, (USD Million)

Table 23 Western Europe Reye’s Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 24 Western Europe Reye’s Syndrome Market by End Users, 2017 – 2023, (USD Million)

Table 25 Eastern Europe Reye’s Syndrome Market by Diagnosis, 2017 – 2023, (USD Million)

Table 26 Eastern Europe Reye’s Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 27 Eastern Europe Reye’s Syndrome Market by End Users, 2017 – 2023, (USD Million)

Table 28 Asia Pacific Reye’s Syndrome Market by Diagnosis, 2017 – 2023, (USD Million)

Table 29 Asia Pacific Reye’s Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 30 Asia Pacific Reye’s Syndrome Market by End Users, 2017 – 2023, (USD Million)

Table 31 Middle East & Africa Reye’s Syndrome Market by Diagnosis, 2017 – 2023, (USD Million)

Table 32 Middle East & Africa Reye’s Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 33 Middle East & Africa Reye’s Syndrome Market by End Users, 2017 – 2023, (USD Million)


LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Reye’s Syndrome Market

Figure 3 Market Dynamics for Global Reye’s Syndrome Market

Figure 4 Global Reye’s Syndrome Market Share, by Diagnosis 2016

Figure 5 Global Reye’s Syndrome Market Share, by Treatment 2016

Figure 6 Global Reye’s Syndrome Market Share, by End Users, 2016

Figure 7 Global Reye’s Syndrome Market Share, by Region, 2016

Figure 8 Americas Reye’s Syndrome Market Share, by Country, 2016

Figure 9 Europe Reye’s Syndrome Market Share, by Country, 2016

Figure 10 Asia Pacific Reye’s Syndrome Market Share, by Country, 2016

Figure 11 Middle East & Africa Reye’s Syndrome Market Share, by Country, 2016

Figure 12 Global Reye’s Syndrome Market: Company Share Analysis, 2016 (%)

Figure 13 ARGON MEDICAL: Key Financials

Figure 14 ARGON MEDICAL: Segmental Revenue

Figure 15 ARGON MEDICAL: Geographical Revenue

Figure 16 AstraZeneca: Key Financials

Figure 17 AstraZeneca: Segmental Revenue

Figure 18 AstraZeneca: Geographical Revenue

Figure 19 BD: Key Financials

Figure 20 BD: Segmental Revenue

Figure 21 BD: Geographical Revenue

Figure 22 Biocon: Key Financials

Figure 23 Biocon: Segmental Revenue

Figure 24 Biocon: Geographical Revenue

Figure 25 CANON MEDICAL SYSTEMS CORPORATION: Key Financials

Figure 26 CANON MEDICAL SYSTEMS CORPORATION: Segmental Revenue

Figure 27 CANON MEDICAL SYSTEMS CORPORATION: Geographical Revenue

Figure 28 Eli Lilly and Company: Key Financials

Figure 29 Eli Lilly and Company: Segmental Revenue

Figure 30 Eli Lilly and Company: Geographical Revenue

Figure 31 General Electric Company: Key Financials

Figure 32 General Electric Company: Segmental Revenue

Figure 33 General Electric Company: Geographical Revenue

Figure 34 Koninklijke Philips N.V.: Key Financials

Figure 35 Koninklijke Philips N.V.: Segmental Revenue

Figure 36 Koninklijke Philips N.V.: Geographical Revenue